{"id":921598,"date":"2025-12-19T16:34:37","date_gmt":"2025-12-19T21:34:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/"},"modified":"2025-12-19T16:34:37","modified_gmt":"2025-12-19T21:34:37","slug":"inovio-reports-inducement-grant-under-inducement-plan-3","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/","title":{"rendered":"INOVIO Reports Inducement Grant Under Inducement Plan"},"content":{"rendered":"<div class=\"xn-newslines\">\n<p class=\"xn-distributor\">PR Newswire<\/p>\n<\/p><\/div>\n<div class=\"xn-content\">\n<p>\n        <span class=\"legendSpanClass\">PLYMOUTH MEETING, Pa.<\/span>, <span class=\"legendSpanClass\">Dec. 19, 2025<\/span> \/PRNewswire\/ &#8212; INOVIO (NASDAQ: INO),\u00a0a biotechnology company focused on developing and commercializing DNA medicines to\u00a0help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the &#8220;Inducement Plan&#8221;).<\/p>\n<div class=\"PRN_ImbeddedAssetReference\" id=\"DivAssetPlaceHolder1\">\n<p>\n          <a href=\"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.html\" target=\"_blank\" rel=\"nofollow\"><br \/>\n            <img decoding=\"async\" src=\"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg\" title=\"(PRNewsfoto\/INOVIO Pharmaceuticals, Inc.)\" alt=\"(PRNewsfoto\/INOVIO Pharmaceuticals, Inc.)\" \/><br \/>\n          <\/a>\n        <\/p>\n<\/p><\/div>\n<p>The Compensation Committee of INOVIO&#8217;s Board of Directors has approved\u00a0the\u00a0award of an option to purchase 24,000\u00a0shares of common stock with a grant date of November 28, 2025\u00a0(the &#8220;Grant Date&#8221;), to a\u00a0newly\u00a0hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).<\/p>\n<p>The stock option has an exercise price of $2.06, the closing price of INOVIO&#8217;s common stock on November 28, 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee&#8217;s continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement under the Inducement Plan.<\/p>\n<p>\n        <b>About INOVIO<br \/><\/b>INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO&#8217;s technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit <a href=\"https:\/\/edge.prnewswire.com\/c\/link\/?t=0&amp;l=en&amp;o=4584946-1&amp;h=375762644&amp;u=http%3A%2F%2Fwww.inovio.com%2F&amp;a=www.inovio.com\" target=\"_blank\" rel=\"nofollow\">www.inovio.com<\/a>.<\/p>\n<p>\n        <b>Contacts<br \/><\/b>Media: Jennie Willson, (267) 429-8567, <a href=\"mailto:communications@inovio.com\" target=\"_blank\" rel=\"nofollow\">communications@inovio.com<\/a><br \/>Investors: Peter Vozzo &#8211; ICR Healthcare, (443) 213-0505,\u00a0<a href=\"mailto:investor.relations@inovio.com\" target=\"_blank\" rel=\"nofollow\">investor.relations@inovio.com<\/a>\u00a0<\/p>\n<p id=\"PURL\">\n        <img loading=\"lazy\" decoding=\"async\" title=\"Cision\" width=\"12\" height=\"12\" alt=\"Cision\" src=\"https:\/\/edge.prnewswire.com\/c\/img\/favicon.png?sn=PH52057&amp;sd=2025-12-19\" \/> View original content to download multimedia:<a id=\"PRNURL\" rel=\"nofollow\" href=\"https:\/\/www.prnewswire.com\/news-releases\/inovio-reports-inducement-grant-under-inducement-plan-302647275.html\" target=\"_blank\">https:\/\/www.prnewswire.com\/news-releases\/inovio-reports-inducement-grant-under-inducement-plan-302647275.html<\/a><\/p>\n<p>SOURCE INOVIO Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n<p>    <img decoding=\"async\" alt=\"\" src=\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=PH52057&amp;Transmission_Id=202512191605PR_NEWS_USPR_____PH52057&amp;DateId=20251219\" style=\"border:0px;width:1px;height:1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>PR Newswire PLYMOUTH MEETING, Pa., Dec. 19, 2025 \/PRNewswire\/ &#8212; INOVIO (NASDAQ: INO),\u00a0a biotechnology company focused on developing and commercializing DNA medicines to\u00a0help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Compensation Committee of INOVIO&#8217;s Board of Directors has approved\u00a0the\u00a0award of an option to purchase 24,000\u00a0shares of common stock with a grant date of November 28, 2025\u00a0(the &#8220;Grant Date&#8221;), to a\u00a0newly\u00a0hired employee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.06, the closing price of INOVIO&#8217;s common stock on November 28, 2025. The stock option will vest &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;INOVIO Reports Inducement Grant Under Inducement Plan&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-921598","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire PLYMOUTH MEETING, Pa., Dec. 19, 2025 \/PRNewswire\/ &#8212; INOVIO (NASDAQ: INO),\u00a0a biotechnology company focused on developing and commercializing DNA medicines to\u00a0help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Compensation Committee of INOVIO&#8217;s Board of Directors has approved\u00a0the\u00a0award of an option to purchase 24,000\u00a0shares of common stock with a grant date of November 28, 2025\u00a0(the &#8220;Grant Date&#8221;), to a\u00a0newly\u00a0hired employee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.06, the closing price of INOVIO&#8217;s common stock on November 28, 2025. The stock option will vest &hellip; Continue reading &quot;INOVIO Reports Inducement Grant Under Inducement Plan&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-19T21:34:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"INOVIO Reports Inducement Grant Under Inducement Plan\",\"datePublished\":\"2025-12-19T21:34:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/\"},\"wordCount\":279,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2310866\\\/INOVIO_v1_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/\",\"name\":\"INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2310866\\\/INOVIO_v1_Logo.jpg\",\"datePublished\":\"2025-12-19T21:34:37+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2310866\\\/INOVIO_v1_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/2310866\\\/INOVIO_v1_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/inovio-reports-inducement-grant-under-inducement-plan-3\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"INOVIO Reports Inducement Grant Under Inducement Plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/","og_locale":"en_US","og_type":"article","og_title":"INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk","og_description":"PR Newswire PLYMOUTH MEETING, Pa., Dec. 19, 2025 \/PRNewswire\/ &#8212; INOVIO (NASDAQ: INO),\u00a0a biotechnology company focused on developing and commercializing DNA medicines to\u00a0help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the &#8220;Inducement Plan&#8221;). The Compensation Committee of INOVIO&#8217;s Board of Directors has approved\u00a0the\u00a0award of an option to purchase 24,000\u00a0shares of common stock with a grant date of November 28, 2025\u00a0(the &#8220;Grant Date&#8221;), to a\u00a0newly\u00a0hired employee in accordance with Nasdaq Listing Rule 5635(c)(4). The stock option has an exercise price of $2.06, the closing price of INOVIO&#8217;s common stock on November 28, 2025. The stock option will vest &hellip; Continue reading \"INOVIO Reports Inducement Grant Under Inducement Plan\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/","og_site_name":"Market Newsdesk","article_published_time":"2025-12-19T21:34:37+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"INOVIO Reports Inducement Grant Under Inducement Plan","datePublished":"2025-12-19T21:34:37+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/"},"wordCount":279,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/","name":"INOVIO Reports Inducement Grant Under Inducement Plan - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg","datePublished":"2025-12-19T21:34:37+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/2310866\/INOVIO_v1_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/inovio-reports-inducement-grant-under-inducement-plan-3\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"INOVIO Reports Inducement Grant Under Inducement Plan"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921598","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=921598"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/921598\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=921598"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=921598"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=921598"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}